Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for NVCR

Stock Name	Novocure Ltd
Ticker	NVCR(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	JE00BYSS4X48
LEI	213800YPP55UMHWA4826

Show aggregate NVCR holdings

News associated with NVCR

NovoCure (NASDAQ:NVCR) Shares Gap Up Following Insider Buying Activity: Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $12.28, but opened at $13.65. NovoCure shares last traded at $13.03, with a volume of 543,802 shares trading hands. Specifically, CEO Ashley Cordova acquired 81,550 shares of the […] - 2025-09-10 02:26:51
Analysts Set NovoCure Limited (NASDAQ:NVCR) Price Target at $28.79: Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average […] - 2025-08-21 04:44:51
Novocure Submits Premarket Approval Application To FDA For TTFields Therapy In Pancreatic Cancer: (RTTNews) - Novocure (NVCR) Wednesday said it has submitted a premarket approval application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. - 2025-08-20 08:50:20
TD Asset Management Inc Sells 204,942 Shares of NovoCure Limited (NASDAQ:NVCR): TD Asset Management Inc decreased its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 81.0% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 48,212 shares of the medical equipment provider’s stock after selling 204,942 shares during the period. TD Asset Management Inc’s holdings in NovoCure […] - 2025-08-05 04:37:19
Y Intercept Hong Kong Ltd Has $419,000 Stock Position in NovoCure Limited (NASDAQ:NVCR): Y Intercept Hong Kong Ltd raised its stake in NovoCure Limited (NASDAQ:NVCR – Free Report) by 25.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,492 shares of the medical equipment provider’s stock after buying an additional 4,723 shares during […] - 2025-07-29 05:56:52
NovoCure (NASDAQ:NVCR) Receives “Equal Weight” Rating from Wells Fargo & Company: Wells Fargo & Company reissued their equal weight rating on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report released on Friday morning, Marketbeat reports. The firm currently has a $14.50 target price on the medical equipment provider’s stock, down from their previous target price of $40.00. Other analysts also recently issued reports about […] - 2025-07-28 04:18:52
Bank of New York Mellon Corp Purchases 2,062 Shares of NovoCure Limited (NASDAQ:NVCR): Bank of New York Mellon Corp grew its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 324,592 shares of the medical equipment provider’s stock after acquiring an […] - 2025-07-25 04:35:07
32,179 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by Jennison Associates LLC: Jennison Associates LLC acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 32,179 shares of the medical equipment provider’s stock, valued at approximately $573,000. Several other large investors also […] - 2025-07-23 06:20:54
Teacher Retirement System of Texas Acquires 3,123 Shares of NovoCure Limited (NASDAQ:NVCR): Teacher Retirement System of Texas raised its holdings in NovoCure Limited (NASDAQ:NVCR – Free Report) by 5.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 62,375 shares of the medical equipment provider’s stock after purchasing an additional 3,123 shares during the quarter. Teacher Retirement System of Texas’ holdings in NovoCure were worth […] - 2025-07-14 04:56:53
LADENBURG THALM/SH SH Begins Coverage on NovoCure (NASDAQ:NVCR): LADENBURG THALM/SH SH began coverage on shares of NovoCure (NASDAQ:NVCR – Get Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $30.00 price target on the medical equipment provider’s stock. LADENBURG THALM/SH SH’s price objective points to a potential upside of 64.93% from the […] - 2025-07-10 04:01:26
California State Teachers Retirement System Sells 635 Shares of NovoCure Limited (NASDAQ:NVCR): California State Teachers Retirement System reduced its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 96,389 shares of the medical equipment provider’s stock after selling 635 shares during the quarter. California […] - 2025-06-06 05:42:57
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages: Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month […] - 2025-06-04 03:06:44
BNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR): BNP Paribas Financial Markets decreased its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 83.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,555 shares of the medical equipment provider’s stock after selling 147,371 shares during the period. BNP Paribas Financial Markets’ holdings in NovoCure were worth $851,000 as of […] - 2025-05-22 04:38:53
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Deutsche Bank AG: Deutsche Bank AG lifted its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 20.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 194,327 shares of the medical equipment provider’s stock after acquiring an additional 33,293 shares during the quarter. Deutsche Bank […] - 2025-05-19 05:06:55
Tower Research Capital LLC TRC Sells 6,669 Shares of NovoCure Limited (NASDAQ:NVCR): Tower Research Capital LLC TRC trimmed its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 76.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,034 shares of the medical equipment provider’s stock after selling 6,669 shares […] - 2025-05-12 04:50:52
NovoCure (NASDAQ:NVCR) and Meihua International Medical Technologies (NASDAQ:MHUA) Head to Head Survey: Meihua International Medical Technologies (NASDAQ:MHUA – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Institutional and Insider Ownership 1.2% of […] - 2025-05-06 02:09:04
Why NovoCure Stock Skyrocketed This Week: Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%. - 2025-04-25 14:21:57
Bank of Montreal Can Acquires New Shares in NovoCure Limited (NASDAQ:NVCR): Bank of Montreal Can purchased a new position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm purchased 8,183 shares of the medical equipment provider’s stock, valued at approximately $244,000. Other institutional investors have also made changes to their positions in the company. Tidal Investments LLC […] - 2025-04-25 05:08:56
Piper Sandler Issues Pessimistic Forecast for NovoCure (NASDAQ:NVCR) Stock Price: NovoCure (NASDAQ:NVCR – Get Free Report) had its price objective reduced by analysts at Piper Sandler from $42.00 to $34.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s target price would indicate a potential upside of 83.29% from the stock’s current […] - 2025-04-25 04:31:12
NovoCure (NASDAQ:NVCR) Lowered to Sell Rating by StockNews.com: NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Friday. Other research analysts have also recently issued research reports about the stock. Piper Sandler reduced their price target on shares of NovoCure from $42.00 to $34.00 and set an “overweight” […] - 2025-04-25 03:10:53
NovoCure Surpasses Q1 Expectations: NovoCure (NASDAQ:NVCR), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street’s e - 2025-04-24 10:25:13
Legal & General Group Plc Reduces Stake in NovoCure Limited (NASDAQ:NVCR): Legal & General Group Plc cut its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 14.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 157,758 shares of the medical equipment provider’s stock after selling 26,654 shares during the quarter. Legal & General Group Plc’s holdings in NovoCure were worth $4,701,000 […] - 2025-04-22 05:44:56
Summit Investment Advisors Inc. Raises Stock Holdings in NovoCure Limited (NASDAQ:NVCR): Summit Investment Advisors Inc. boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,141 shares of the medical equipment provider’s stock after acquiring an additional 708 shares […] - 2025-04-21 04:56:57
StockNews.com Downgrades NovoCure (NASDAQ:NVCR) to Sell: NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday. Other research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares […] - 2025-04-11 05:18:59
Pictet Asset Management Holding SA Boosts Stake in NovoCure Limited (NASDAQ:NVCR): Pictet Asset Management Holding SA boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 19.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,919 shares of the medical equipment provider’s stock after acquiring an additional […] - 2025-04-10 05:37:15
21,600 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS acquired a new stake in NovoCure Limited (NASDAQ:NVCR – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 21,600 shares of the medical equipment provider’s stock, valued at approximately $644,000. A number of other hedge funds have also modified their holdings of […] - 2025-04-02 05:16:54
NovoCure Limited (NASDAQ:NVCR) Receives $35.80 Consensus PT from Analysts: Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective […] - 2025-03-24 04:40:48
NovoCure (NASDAQ:NVCR) Raised to “Hold” at StockNews.com: NovoCure (NASDAQ:NVCR – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday. Other analysts have also issued reports about the stock. Wedbush reissued a “neutral” rating and set a $29.00 target price on shares of NovoCure in a […] - 2025-03-20 03:44:55
Charles Schwab Investment Management Inc. Purchases 11,771 Shares of NovoCure Limited (NASDAQ:NVCR): Charles Schwab Investment Management Inc. boosted its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 1.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 836,214 shares of the medical equipment provider’s stock after buying an additional 11,771 shares during the period. […] - 2025-03-19 05:52:57
SBI Securities Co. Ltd. Invests $70,000 in NovoCure Limited (NASDAQ:NVCR): SBI Securities Co. Ltd. acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 2,341 shares of the medical equipment provider’s stock, valued at approximately $70,000. Several other institutional investors have also added to or reduced their stakes in the stock. Brooklyn Investment Group bought […] - 2025-03-10 06:07:07

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc NVCR holdings

Date	Number of NVCR Shares Held	Base Market Value of NVCR Shares	Local Market Value of NVCR Shares	Change in NVCR Shares Held	Change in NVCR Base Value	Current Price per NVCR Share Held	Previous Price per NVCR Share Held
2025-11-12 (Wednesday)	63,225	USD 718,236	USD 718,236	-208	USD -34,079	USD 11.36	USD 11.86
2025-11-11 (Tuesday)	63,433	USD 752,315	USD 752,315	0	USD 37,425	USD 11.86	USD 11.27
2025-11-10 (Monday)	63,433	USD 714,890	USD 714,890	0	USD 22,202	USD 11.27	USD 10.92
2025-11-07 (Friday)	63,433	USD 692,688	USD 692,688	0	USD -22,202	USD 10.92	USD 11.27
2025-11-06 (Thursday)	63,433	USD 714,890	USD 714,890	-208	USD -23,982	USD 11.27	USD 11.61
2025-11-05 (Wednesday)	63,641	USD 738,872	USD 738,872	-2,080	USD -49,780	USD 11.61	USD 12
2025-11-04 (Tuesday)	65,721	USD 788,652	USD 788,652	-416	USD -20,204	USD 12	USD 12.23
2025-11-03 (Monday)	66,137	USD 808,856	USD 808,856	-416	USD -43,688	USD 12.23	USD 12.81
2025-10-31 (Friday)	66,553	USD 852,544	USD 852,544	0	USD -665	USD 12.81	USD 12.82
2025-10-30 (Thursday)	66,553	USD 853,209	USD 853,209	0	USD -43,925	USD 12.82	USD 13.48
2025-10-29 (Wednesday)	66,553	USD 897,134	USD 897,134	0	USD 7,320	USD 13.48	USD 13.37
2025-10-28 (Tuesday)	66,553	USD 889,814	USD 889,814	624	USD -5,502	USD 13.37	USD 13.58
2025-10-27 (Monday)	65,929	USD 895,316	USD 895,316	0	USD -11,208	USD 13.58	USD 13.75

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NVCR by Blackrock for IE00B3VWM098

Show aggregate share trades of NVCR

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-12 SELL -208 11.965 11.330 11.393 USD -2,370 18.04 Profit of 1,383 on sale
2025-11-06 SELL -208 11.500 11.240 11.266 USD -2,343 18.18 Profit of 1,439 on sale
2025-11-05 SELL -2,080 12.050 11.305 11.380 USD -23,669 18.22 Profit of 14,222 on sale
2025-11-04 SELL -416 12.214 11.860 11.895 USD -4,948 18.25 Profit of 2,643 on sale
2025-11-03 SELL -416 12.800 12.190 12.251 USD -5,096 18.28 Profit of 2,508 on sale
2025-10-28 BUY 624 13.370 13.770 13.730 USD 8,568 18.39
2025-10-24 SELL -208 13.750 14.170 14.128 USD -2,939 18.44 Profit of 898 on sale
2025-10-15 BUY 1,248 14.180 14.190 14.189 USD 17,708 18.62
2025-10-02 BUY 208 14.050 14.120 14.113 USD 2,936 18.67
2025-09-30 BUY 416 12.920 13.040 13.028 USD 5,420 18.73
2025-09-11 BUY 832 12.730 12.830 12.820 USD 10,666 18.90
2025-08-21 SELL -175 11.910 11.975 11.969 USD -2,094 18.94 Profit of 1,221 on sale
2025-07-31 BUY 525 11.570 12.380 12.299 USD 6,457 19.03
2025-06-30 SELL -350 17.800 18.700 18.610 USD -6,514 19.39 Profit of 273 on sale
2025-06-25 SELL -175 17.325 17.350 17.348 USD -3,036 19.43 Profit of 364 on sale
2025-06-20 SELL -350 16.690 17.070 17.032 USD -5,961 19.49 Profit of 859 on sale
2025-05-23 BUY 175 18.540 18.790 18.765 USD 3,284 19.77
2025-05-19 SELL -175 17.960 17.990 17.987 USD -3,148 19.83 Profit of 323 on sale
2025-05-15 SELL -525 17.590 17.620 17.617 USD -9,249 19.87 Profit of 1,182 on sale
2025-05-12 SELL -175 18.570 18.770 18.750 USD -3,281 19.92 Profit of 205 on sale
2025-05-09 SELL -175 17.380 17.690 17.659 USD -3,090 19.94 Profit of 400 on sale
2025-04-30 SELL -175 18.140 18.320 18.302 USD -3,203 20.11 Profit of 316 on sale
2025-04-24 SELL -350 18.550 19.245 19.176 USD -6,711 20.18 Profit of 351 on sale
2025-04-17 SELL -175 15.580 15.850 15.823 USD -2,769 20.39 Profit of 799 on sale
2025-04-15 SELL -525 16.460 16.860 16.820 USD -8,831 20.48 Profit of 1,923 on sale
2025-04-14 SELL -525 16.550 17.055 17.005 USD -8,927 20.53 Profit of 1,849 on sale
2025-04-09 SELL -700 16.950 17.150 17.130 USD -11,991 20.66 Profit of 2,473 on sale
2025-04-07 SELL -1,225 16.610 17.403 17.324 USD -21,222 20.77 Profit of 4,223 on sale
2025-04-04 SELL -1,750 16.490 16.800 16.769 USD -29,346 20.82 Profit of 7,092 on sale
2025-03-31 BUY 175 17.820 18.580 18.504 USD 3,238 20.93
2025-03-19 SELL -350 19.320 19.561 19.537 USD -6,838 21.13 Profit of 559 on sale
2025-03-14 SELL -1,050 19.490 20.485 20.386 USD -21,405 21.20 Profit of 859 on sale
2025-03-13 SELL -352 20.060 20.870 20.789 USD -7,318 21.22 Profit of 152 on sale
2025-03-12 SELL -5,984 20.620 21.550 21.457 USD -128,399 21.23 Loss of -1,366 on sale
2025-03-07 SELL -352 20.180 20.500 20.468 USD -7,205 21.26 Profit of 278 on sale
2025-03-06 SELL -528 19.260 19.440 19.422 USD -10,255 21.29 Profit of 985 on sale
2025-03-03 SELL -176 18.410 19.060 18.995 USD -3,343 21.42 Profit of 427 on sale
2025-02-28 BUY 9,342 19.070 19.280 19.259 USD 179,918 21.46
2025-02-26 SELL -148 21.960 22.300 22.266 USD -3,295 21.49 Loss of -115 on sale
2025-02-25 SELL -444 21.000 21.400 21.360 USD -9,484 21.50 Profit of 60 on sale
2025-02-18 BUY 740 22.050 22.560 22.509 USD 16,657 21.47
2025-02-13 BUY 148 21.710 21.820 21.809 USD 3,228 21.42
2025-02-12 BUY 148 21.370 21.400 21.397 USD 3,167 21.43
2025-02-11 BUY 444 21.210 21.660 21.615 USD 9,597 21.43
2025-02-06 BUY 1,332 22.930 24.190 24.064 USD 32,053 21.37
2025-01-30 BUY 4,864 25.510 26.465 26.370 USD 128,261 21.00
2025-01-27 BUY 134 25.380 26.360 26.262 USD 3,519 20.64
2024-12-30 BUY 670 30.080 30.810 30.737 USD 20,594 19.71
2024-12-06 BUY 536 27.960 28.380 28.338 USD 15,189 18.80
2024-12-05 BUY 134 26.600 29.315 29.044 USD 3,892 18.53
2024-12-04 BUY 670 29.230 31.283 31.078 USD 20,822 18.15
2024-11-29 BUY 670 20.040 20.240 20.220 USD 13,547 17.11
2024-11-27 BUY 536 19.690 19.770 19.762 USD 10,592 16.88
2024-11-26 BUY 134 17.880 18.740 18.654 USD 2,500 16.84
2024-11-21 BUY 670 17.090 17.220 17.207 USD 11,529 16.68
2024-11-20 BUY 402 16.860 17.350 17.301 USD 6,955 16.67
2024-11-18 BUY 1,608 15.730 16.160 16.117 USD 25,916 16.74
2024-11-12 BUY 1,072 17.820 18.380 18.324 USD 19,643 16.66
2024-11-08 BUY 665 17.440 18.670 18.547 USD 12,334 16.61
2024-11-07 BUY 1,995 17.650 18.100 18.055 USD 36,020 16.53
2024-11-06 BUY 266 18.100 18.450 18.415 USD 4,898 16.40
2024-10-31 BUY 133 15.180 16.640 16.494 USD 2,194 16.53
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-12	SELL	-208	11.965	11.330	11.393	USD -2,370	18.04 Profit of 1,383 on sale
2025-11-06	SELL	-208	11.500	11.240	11.266	USD -2,343	18.18 Profit of 1,439 on sale
2025-11-05	SELL	-2,080	12.050	11.305	11.380	USD -23,669	18.22 Profit of 14,222 on sale
2025-11-04	SELL	-416	12.214	11.860	11.895	USD -4,948	18.25 Profit of 2,643 on sale
2025-11-03	SELL	-416	12.800	12.190	12.251	USD -5,096	18.28 Profit of 2,508 on sale
2025-10-28	BUY	624	13.370	13.770	13.730	USD 8,568	18.39
2025-10-24	SELL	-208	13.750	14.170	14.128	USD -2,939	18.44 Profit of 898 on sale
2025-10-15	BUY	1,248	14.180	14.190	14.189	USD 17,708	18.62
2025-10-02	BUY	208	14.050	14.120	14.113	USD 2,936	18.67
2025-09-30	BUY	416	12.920	13.040	13.028	USD 5,420	18.73
2025-09-11	BUY	832	12.730	12.830	12.820	USD 10,666	18.90
2025-08-21	SELL	-175	11.910	11.975	11.969	USD -2,094	18.94 Profit of 1,221 on sale
2025-07-31	BUY	525	11.570	12.380	12.299	USD 6,457	19.03
2025-06-30	SELL	-350	17.800	18.700	18.610	USD -6,514	19.39 Profit of 273 on sale
2025-06-25	SELL	-175	17.325	17.350	17.348	USD -3,036	19.43 Profit of 364 on sale
2025-06-20	SELL	-350	16.690	17.070	17.032	USD -5,961	19.49 Profit of 859 on sale
2025-05-23	BUY	175	18.540	18.790	18.765	USD 3,284	19.77
2025-05-19	SELL	-175	17.960	17.990	17.987	USD -3,148	19.83 Profit of 323 on sale
2025-05-15	SELL	-525	17.590	17.620	17.617	USD -9,249	19.87 Profit of 1,182 on sale
2025-05-12	SELL	-175	18.570	18.770	18.750	USD -3,281	19.92 Profit of 205 on sale
2025-05-09	SELL	-175	17.380	17.690	17.659	USD -3,090	19.94 Profit of 400 on sale
2025-04-30	SELL	-175	18.140	18.320	18.302	USD -3,203	20.11 Profit of 316 on sale
2025-04-24	SELL	-350	18.550	19.245	19.176	USD -6,711	20.18 Profit of 351 on sale
2025-04-17	SELL	-175	15.580	15.850	15.823	USD -2,769	20.39 Profit of 799 on sale
2025-04-15	SELL	-525	16.460	16.860	16.820	USD -8,831	20.48 Profit of 1,923 on sale
2025-04-14	SELL	-525	16.550	17.055	17.005	USD -8,927	20.53 Profit of 1,849 on sale
2025-04-09	SELL	-700	16.950	17.150	17.130	USD -11,991	20.66 Profit of 2,473 on sale
2025-04-07	SELL	-1,225	16.610	17.403	17.324	USD -21,222	20.77 Profit of 4,223 on sale
2025-04-04	SELL	-1,750	16.490	16.800	16.769	USD -29,346	20.82 Profit of 7,092 on sale
2025-03-31	BUY	175	17.820	18.580	18.504	USD 3,238	20.93
2025-03-19	SELL	-350	19.320	19.561	19.537	USD -6,838	21.13 Profit of 559 on sale
2025-03-14	SELL	-1,050	19.490	20.485	20.386	USD -21,405	21.20 Profit of 859 on sale
2025-03-13	SELL	-352	20.060	20.870	20.789	USD -7,318	21.22 Profit of 152 on sale
2025-03-12	SELL	-5,984	20.620	21.550	21.457	USD -128,399	21.23 Loss of -1,366 on sale
2025-03-07	SELL	-352	20.180	20.500	20.468	USD -7,205	21.26 Profit of 278 on sale
2025-03-06	SELL	-528	19.260	19.440	19.422	USD -10,255	21.29 Profit of 985 on sale
2025-03-03	SELL	-176	18.410	19.060	18.995	USD -3,343	21.42 Profit of 427 on sale
2025-02-28	BUY	9,342	19.070	19.280	19.259	USD 179,918	21.46
2025-02-26	SELL	-148	21.960	22.300	22.266	USD -3,295	21.49 Loss of -115 on sale
2025-02-25	SELL	-444	21.000	21.400	21.360	USD -9,484	21.50 Profit of 60 on sale
2025-02-18	BUY	740	22.050	22.560	22.509	USD 16,657	21.47
2025-02-13	BUY	148	21.710	21.820	21.809	USD 3,228	21.42
2025-02-12	BUY	148	21.370	21.400	21.397	USD 3,167	21.43
2025-02-11	BUY	444	21.210	21.660	21.615	USD 9,597	21.43
2025-02-06	BUY	1,332	22.930	24.190	24.064	USD 32,053	21.37
2025-01-30	BUY	4,864	25.510	26.465	26.370	USD 128,261	21.00
2025-01-27	BUY	134	25.380	26.360	26.262	USD 3,519	20.64
2024-12-30	BUY	670	30.080	30.810	30.737	USD 20,594	19.71
2024-12-06	BUY	536	27.960	28.380	28.338	USD 15,189	18.80
2024-12-05	BUY	134	26.600	29.315	29.044	USD 3,892	18.53
2024-12-04	BUY	670	29.230	31.283	31.078	USD 20,822	18.15
2024-11-29	BUY	670	20.040	20.240	20.220	USD 13,547	17.11
2024-11-27	BUY	536	19.690	19.770	19.762	USD 10,592	16.88
2024-11-26	BUY	134	17.880	18.740	18.654	USD 2,500	16.84
2024-11-21	BUY	670	17.090	17.220	17.207	USD 11,529	16.68
2024-11-20	BUY	402	16.860	17.350	17.301	USD 6,955	16.67
2024-11-18	BUY	1,608	15.730	16.160	16.117	USD 25,916	16.74
2024-11-12	BUY	1,072	17.820	18.380	18.324	USD 19,643	16.66
2024-11-08	BUY	665	17.440	18.670	18.547	USD 12,334	16.61
2024-11-07	BUY	1,995	17.650	18.100	18.055	USD 36,020	16.53
2024-11-06	BUY	266	18.100	18.450	18.415	USD 4,898	16.40
2024-10-31	BUY	133	15.180	16.640	16.494	USD 2,194	16.53

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NVCR

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	146,296	0	421,759	34.7%
2025-09-18	109,188	0	560,456	19.5%
2025-09-17	119,469	301	498,067	24.0%
2025-09-16	191,175	400	705,469	27.1%
2025-09-15	272,067	0	1,107,083	24.6%
2025-09-12	109,857	0	270,874	40.6%
2025-09-11	218,116	0	689,642	31.6%
2025-09-10	230,953	95	658,890	35.1%
2025-09-09	234,044	4,681	645,307	36.3%
2025-09-08	339,725	3,440	815,445	41.7%
2025-09-05	166,892	0	408,146	40.9%
2025-09-04	257,672	43,716	678,816	38.0%
2025-09-03	177,114	0	351,319	50.4%
2025-09-02	137,400	0	404,389	34.0%
2025-08-29	160,727	0	352,263	45.6%
2025-08-28	191,578	3,553	657,423	29.1%
2025-08-27	150,551	7,255	425,992	35.3%
2025-08-26	119,516	0	645,276	18.5%
2025-08-25	171,812	0	553,315	31.1%
2025-08-22	94,300	0	476,262	19.8%
2025-08-21	143,620	0	367,651	39.1%
2025-08-20	190,862	110	434,326	43.9%
2025-08-19	137,859	0	457,522	30.1%
2025-08-18	179,056	0	473,961	37.8%
2025-08-15	169,569	8	564,351	30.0%
2025-08-14	212,081	0	504,691	42.0%
2025-08-13	268,074	0	1,199,258	22.4%
2025-08-12	212,713	4,365	614,711	34.6%
2025-08-11	194,203	4	512,173	37.9%
2025-08-08	254,996	1,239	736,775	34.6%
2025-08-07	243,762	608	804,784	30.3%
2025-08-06	229,740	3,802	734,190	31.3%
2025-08-05	463,496	1,061	2,536,451	18.3%
2025-08-04	323,993	53	954,167	34.0%
2025-08-01	378,472	0	1,053,485	35.9%
2025-07-31	479,008	2,516	1,888,144	25.4%
2025-07-30	452,345	0	1,441,401	31.4%
2025-07-29	329,608	1,502	1,070,202	30.8%
2025-07-28	306,605	0	1,104,404	27.8%
2025-07-25	533,024	42,563	1,609,831	33.1%
2025-07-24	763,758	71,574	2,115,331	36.1%
2025-07-23	145,473	921	417,907	34.8%
2025-07-22	113,998	0	328,855	34.7%
2025-07-21	140,312	0	474,581	29.6%
2025-07-18	96,636	400	339,936	28.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE